![]() ![]() Clinical consequences of CVD include chronic edema, lower limb pain and discomfort, reduced mobility, hyperpigmentation, stasis dermatitis and venous ulcers. Keywords: Vekroosan Calf compression Chronic venous disease IntroductionĬhronic venous disease (CVD) of the lower limbs is caused by abnormalities of the venous wall and valves that lead to obstruction or reflux of blood flow in the veins. Eighty-seven percent of patients tolerated the device well.Ĭonclusions: Our study shows that use of mobile IPC devices, such as Vekroosan, is safe and effective in the treatment of CVD, can be used while mobilizing and can achieve results comparable to non-mobile devices. 21.9 cm, P < 0.01), also with mobilization. A significant decrease was seen in calf swelling after calf compression (31.3 vs. ![]() On average, the PFV pressure increased by 10.7 cm/s when compared to baseline. 32.4 cm/s, P < 0.001), even when patients mobilize. There was a significant increase in femoral PFV pressure in post-compression measurement when compared to the pre-compression measurement (43.1 vs. Results: Vekroosan was able to show significant clinical benefit in 45 patients (80%). Methods: In 56 patients, Doppler ultrasonography was used to measure venous blood peak flow velocity (PFV) at external iliac, common femoral, distal superficial femoral and popliteal vein levels both before and after application of Vekroosan calf compressor for comparison. This observational study aimed to note the use, effects and tolerance of a mobile intermittent pneumatic calf compression (IPC) device, Vekroosan ® (DVT Solution P/L). Background: Compression therapy is an essential part of chronic venous disorder (CVD) treatment in reducing associated complications.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |